{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:07:05Z","timestamp":1774926425196,"version":"3.50.1"},"reference-count":35,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Phase 2 portion of this study evaluated safety and efficacy of polatuzumab vedotin 1.8\u2009mg\/kg and venetoclax 800\u2009mg, plus fixed\u2010dose obinutuzumab 1000\u2009mg or rituximab 375\u2009mg\/m<jats:sup>2<\/jats:sup> in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) or diffuse large B\u2010cell lymphoma (DLBCL), respectively. Patients with complete response (CR) or partial response (PR)\/stable disease (FL) or CR\/PR (DLBCL) at end of induction (EOI; six 21\u2010day\u2009cycles) received post\u2010induction therapy with venetoclax and obinutuzumab or rituximab, respectively. Primary endpoint was CR rate at EOI. Safety\u2010evaluable populations included 74 patients (FL cohort; median age 64\u2009years; progression of disease within 24\u2009months on first\u2010line treatment, 25.7%; FL International Prognostic Index 3\u20135, 54.1%; \u22652 previous therapies, 74.3%) and 57 patients (DLBCL cohort; median age 65\u2009years; International Prognostic Index 3\u20135, 54.4%; \u22652 previous therapies, 77.2%). The most common non\u2010hematologic adverse events (mostly Grades 1\u20132) in the FL and DLBCL cohorts were diarrhea (55.4% and 47.4%, respectively) and nausea (47.3% and 36.8%); neutropenia was the most common Grades 3\u20134 toxicity (39.2% and 52.6%). Efficacy\u2010evaluable populations included patients treated at the recommended Phase 2 dose (FL, <jats:italic>n<\/jats:italic>\u2009=\u200949; DLBCL, <jats:italic>n<\/jats:italic>\u2009=\u200948). CR rates at EOI were 59.2% (FL) and 31.3% (DLBCL); median progression\u2010free survival was 22.8\u2009months (95% confidence interval [CI], 14.5\u2014not evaluable) and 4.6\u2009months (95% CI, 3.6\u20138.1), respectively. Polatuzumab vedotin plus venetoclax and obinutuzumab\/rituximab had acceptable safety in patients with R\/R FL or DLBCL, with promising response rates in R\/R FL, including high\u2010risk patients.<\/jats:p>","DOI":"10.1002\/ajh.27341","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T10:30:18Z","timestamp":1714732218000},"page":"1281-1289","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Polatuzumab vedotin, venetoclax, and an <scp>anti\u2010CD20<\/scp> monoclonal antibody in relapsed\/refractory B\u2010cell <scp>non\u2010Hodgkin<\/scp> lymphoma"],"prefix":"10.1002","volume":"99","author":[{"given":"Sam","family":"Yuen","sequence":"first","affiliation":[{"name":"Calvary Mater Newcastle Hospital  Waratah New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-9672","authenticated-orcid":false,"given":"Tycel J.","family":"Phillips","sequence":"additional","affiliation":[{"name":"University of Michigan Comprehensive Cancer Center  Ann Arbor Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajat","family":"Bannerji","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey  New Brunswick New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Marlton","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital  Brisbane Queensland Australia"},{"name":"Faculty of Medicine The University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Gritti","sequence":"additional","affiliation":[{"name":"ASST Papa Giovanni XXIII  Bergamo Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre Royal Melbourne Hospital, and University of Melbourne  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Johnston","sequence":"additional","affiliation":[{"name":"Royal Hobart Hospital (RHH)  Hobart Tasmania Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Arthur","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital (RNSH)  St Leonards New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Dodero","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Sharma","sequence":"additional","affiliation":[{"name":"Syneos Health  Raleigh North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Hirata","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Musick","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"The Winship Cancer Institute of Emory University  Atlanta Georgia USA"},{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center, CPRIT Scholar in Cancer Research  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4842"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"e_1_2_9_7_1","first-page":"E24","article-title":"Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed\/refractory non\u2010Hodgkin lymphoma: a phase IB\/II study","volume":"97","author":"Phillips T","year":"2021","journal-title":"Am J Hematol"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30026-2"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-CT133"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26809"},{"key":"e_1_2_9_12_1","first-page":"231","article-title":"International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use","volume":"48","year":"1997","journal-title":"Int Dig Health Legis"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S267569"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"e_1_2_9_19_1","first-page":"1","article-title":"Expanding access to chimeric antigen receptor T\u2010cell therapies: challenges and opportunities","volume":"40","author":"Kansagra A","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145872"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00072-2"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007512"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16069"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26301"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.275958"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30120-4"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.11.004"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26151"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.27341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T18:51:58Z","timestamp":1718131918000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.27341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1002\/ajh.27341"],"URL":"https:\/\/doi.org\/10.1002\/ajh.27341","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"2023-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}